Based on alterations of the microbiome between baseline and 1-week as the early phase of dynamic change in the gut microbiome, insulin resistance was improved after 1 week of treatment as reflected by the HOMA-IR (Figure 3C), and this may affect the normalized AUC percentage of insulin that decreased significantly and improved the hyperglycemia from baseline to 1 week in the D-LED PBM group. The gene discussed is INS; the disease is Insulin resistance.